Acura Pharmaceuticals borrows $200,000 from Abuse Deterrent Pharma; note principal reaches $11,294,279

ACURA PHARMACEUTICALS, INC

Acura received $100,000 loans from Abuse Deterrent Pharma on Sept 18 and Oct 2, 2026, raising the secured note principal to $11,294,279.
Accrued interest was about $1,365,000 as of Sept 30, 2026; the note bears 5.25%, with overdue amounts at 7.5%.
Absent additional financing by mid-October 2026, Acura says it may scale back operations, furlough or lay off employees, terminate operations, or seek bankruptcy protection.
Events of default include failure to pay principal or interest continuing 5 days, bankruptcy events, and inability to pay debts as they come due.
Exhibit 99.1 lists Loans #51 through #66, including Loan #66 dated Oct 2, 2026 for $100,000.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.